Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Aclaris Therapeutis (NASDAQ: ACRS).The analyst commented, "Our KOLs like that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE